Herein, we describe our assessment of the oncolytic potential of three TPV recombinants, TPV/eGFP, TPV/∆66R/m-CCL-2/mCherry, and TPV/∆66R/m-IL-2/mCherry, against human pancreatic cancer xenografts in an immunodeficient, athymic nude mouse model and an immunocompetent, athymic nude mouse model following adoptive transfer of CD3+ T cells. Here, CCL2 is linked to pancreatic neoplasm.